1. |
王召华, 李小虎, 钱银锋, 等. MRI对胰腺导管内乳头状粘液瘤良恶性的诊断价值. 医学信息, 2019, 32(14): 166-169.
|
2. |
Longnecker DS, Adler G, Hruban RH, et al. Intraductal papillary mucinous neoplasms of the pancreas//Hamilton SR, Aaltonen LA. WHO classification of tumors of the digestive system. Lyon: IARC Press, 2014: 237-240.
|
3. |
Sakorafas GH, Smyrnioyis V, Reid-Lombardo KM, et al. Primary pancreatic cystic neoplasms revisitied. Part Ⅲ. Intraductal papillary mucinous neoplasms. Surg Oncol, 2011, 20(2): 109-118.
|
4. |
Laffan TA, Horton KM, Klein AP, et al. Prevalence of unsuspected pancreatic cysts on MDCT. AJR Am J Roentgenol, 2008, 191(3): 802-807.
|
5. |
秦国初, 周科峰, 何健, 等. 胰腺实性假乳头状瘤15例CT及MR诊断. 医学影像学杂志, 2012, 22(10): 1699-1702.
|
6. |
Tanaka M. Controversies in the management of pancreatic IPMN. Nat Rev Gastroenterol Hepatol, 2011, 8(1): 56-60.
|
7. |
周英文, 征锦. 胰腺导管内乳头状黏液瘤的影像学诊断进展. 中华消化病与影像杂志(电子版), 2015, 5(6): 315-318.
|
8. |
严力, 陈永亮, 张文智, 等. 胰腺黏液性囊性肿瘤的临床病理特点和CT影像学特征. 中华肿瘤杂志, 2014, 36(6): 446-450.
|
9. |
刘英娜, 肖新广, 李润华, 等. 多层螺旋CT对胰腺导管内乳头状粘液性肿瘤的诊断及鉴别. 现代医用影像学, 2019, 28(2): 310, 314.
|
10. |
娄纪祥, 夏阳, 詹雅珍, 等. MSCT与MRI对胰腺导管内乳头状粘液性肿瘤(IPMN)的诊断价值和临床评估. 浙江创伤外科, 2016, 21(5): 1002-1003, 1004.
|
11. |
Kim TH, Woo YS, Chon HK, et al. Predictors of malignancy in “Pure” branch-duct intraductal papillary mucinous neoplasm of the pancreas without enhancing mural nodules on CT imaging: A Nationwide Multicenter Study. Gut Liver, 2018, 12(5): 583-590.
|
12. |
Choi SY, Kim JH, Yu MH, et al. Diagnostic performance and imaging features for predicting the malignant potential of intraductal papillary mucinous neoplasm of the pancreas: a comparison of EUS, contrast-enhanced CT and MRI. Abdom Radiol (NY), 2017, 42(5): 1449-1458.
|
13. |
Lee JE, Choi SY, Min JH, et al. Determining malignant potential of intraductal papillary mucinous neoplasm of the pancreas: CT versus MRI by using Revised 2017 International Consensus Guidelines. Radiology, 2019, 293(1): 134-143.
|
14. |
孙勤学, 陈振东, 赵亦军, 等. 胰腺导管内乳头状粘液性肿瘤的影像分析. 医学影像学杂志, 2019, 29(6): 993-996.
|
15. |
靳二虎, 苏天昊, 马大庆. 胰腺MRI、MRS和MRCP检查与正常表现. 国际医学放射学杂志, 2012, 35(4): 365-370.
|
16. |
Kang KM, Lee JM, Shin CI, et al. Added value of diffusion-weighted imaging to MR cholangiopancreatography with unenhanced mr imaging for predicting malignancy or invasiveness of intraductal papillary mucinous neoplasm of the pancreas. J Magn Reson Imaging, 2013, 38(3): 555-563.
|
17. |
Ogawa T, Horaguchi J, Fujita N, et al. Diffusion-weighted magnetic resonance imaging for evaluating the histological degree of malignancy in patients with intraductal papillary mucinous neoplasm. J Hepatobiliary Pancreat Sci, 2014, 21(11): 801-808.
|
18. |
Jang KM, Kim SH, Min JH, et al. Value of diffusion-weighted MRI for differentiating malignant from benign intraductal papillary mucinous neoplasms of the pancreas. AJR Am J Roentgenol, 2014, 203(5): 992-1000.
|
19. |
Kartalis N, Lindholm TL, Aspelin P, et al. Diffusion-weighted magnetic resonance imaging of pancreas tumours. Eur Radiol, 2009, 19(8): 1981-190.
|
20. |
Lim J, Allen PJ. The diagnosis and management of intraductal papillary mucinous neoplasms of the pancreas: has progress been made? Updates Surg, 2019, 71(2): 209-216.
|
21. |
Sun M, Kang L, Cui Y, et al. Application of a novel targeting nanoparticle contrast agent combined with magnetic resonance imaging in the diagnosis of intraductal papillary mucinous neoplasm. Exp Ther Med, 2018, 16(2): 1216-1224.
|
22. |
李月月, 徐选福. 内镜超声在胰腺导管乳头状黏液性肿瘤中的诊断价值. 医学影像学杂志, 2018, 18(2): 139-142.
|
23. |
Harima H, Kaino S, Shinoda S, et al. Differential diagnosis of benign and malignant branch duct intraductal papillary mucinous neoplasm using contrast-enhanced endoscopic ultrasonography. World J Gastroenterol, 2015, 21(20): 6252-6260.
|
24. |
Yamashita Y, Ueda K, Itonaga M, et al. Usefulness of contrast-enhanced endoscopic sonography for discriminating mural nodules from mucous clots in intraductal papillary mucinous neoplasms: a single-center prospective study. J Ultrasound Med, 2013, 32(1): 61-68.
|
25. |
Tanaka M, Fernández-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology, 2012, 12(3): 183-197.
|
26. |
Hwang J, Kim YK, Min JH, et al. Comparison between MRI with MR cholangiopancreatography and endoscopic ultrasonography for differentiating malignant from benign mucinous neoplasms of the pancreas. Eur Radiol, 2018, 28(1): 179-187.
|
27. |
Wilson CB. PET scanning in oncology. Eur J Cancer, 1992, 28(2-3): 508-510.
|
28. |
Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med, 1991, 32(4): 623-648.
|
29. |
Tomimaru Y, Takeda Y, Tatsumi M, et al. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography in differential diagnosis of benign and malignant intraductal papillary-mucinous neoplasm of the pancreas. Oncol Rep, 2010, 24(3): 613-620.
|
30. |
Hong HS, Yun M, Cho A, et al. The utility of F-18 FDG PET/CT in the evaluation of pancreatic intraductal papillary mucinous neoplasm. Clin Nucl Med, 2010, 35(10): 776-779.
|
31. |
Baiocchi GL, Bertagna F, Gheza F, et al. Searching for indicators of malignancy in pancreatic intraductal papillary mucinous neoplasms: the value of 18FDG-PET confirmed. Ann Surg Oncol, 2012, 19(11): 3574-3580.
|
32. |
Pedrazzoli S, Sperti C, Pasquali C, et al. Comparison of International Consensus Guidelines versus 18-FDG PET in detecting malignancy of intraductal papillary mucinous neoplasms of the pancreas. Ann Surg, 2011, 254(6): 971-976.
|
33. |
Roch AM, Barron MR, Tann M, et al. Does PET with CT have clinical utility in the management of patients with intraductal papillary mucinous neoplasm? J Am Coll Surg, 2015, 221(1): 48-56.
|
34. |
Yamashita YI, Okabe H, Hayashi H, et al. Usefulness of 18-FDG PET/CT in detecting malignancy in intraductal papillary mucinous neoplasms of the pancreas. Anticancer Res, 2019, 39(5): 2493-2499.
|
35. |
Ohta K, Tanada M, Sugawara Y, et al. Usefulness of positron emission tomography (PET)/contrast-enhanced computed tomography (CE-CT) in discriminating between malignant and benign intraductal papillary mucinous neoplasms (IPMNs). Pancreatology, 2017, 17(6): 911-919.
|